Citatuzumab bogatox - Eleven Biotherapeutics

Drug Profile

Citatuzumab bogatox - Eleven Biotherapeutics

Alternative Names: VB6-845; VB6-845d

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Viventia Biotech
  • Developer Eleven Biotherapeutics
  • Class Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors; Ribosomal protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 24 Nov 2017 Phase I development is underway for Solid tumours (Eleven Therapeutics pipeline, November 2017)
  • 24 Nov 2017 Citatuzumab bogatox is available for licensing as of 20 Nov 2017.
  • 20 Nov 2017 Eleven Biotherapeutics plans to file an IND application for citatuzumab bogatox
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top